Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).

Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).

Curr Cancer Drug Targets. 2016 May 12;

Authors: Gao W, Zhang J, Xiang J, Zhang L, Wu C, Dhal PK, Chen B

Abstract
Antibody-drug conjugates (ADCs) take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells. The recent approval of Adcetris™ and Kadcyla™ as well as emerging data from numerous ongoing clinical trials underscore the role of ADCs as a new therapeutic option for cancer patients. However, conventional conjugation methods generally result in a heterogeneous mixture of ADCs, which can result in significant therapeutic liabilities and can lead to complicated manufacturing processes. The increased understanding from the clinical investigation of current ADCs and site-specific bio-conjugation technologies has enabled scientists to accelerate the discovery and development of the next generation ADCs with defined and homogeneous composition. The present manuscript reviews the recent advances and trends in the research and development of novel ADCs obtained by site-specific conjugation method.

PMID: 27174056 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/1Wx4ZXN
via IFTTT

G9a - an Appealing Antineoplastic Target.

G9a - an Appealing Antineoplastic Target.

Curr Cancer Drug Targets. 2016 May 12;

Authors: Chen WL, Sun HP, Li DD, Wang ZH, You QD, Guo XK

Abstract
G9a is the primary enzyme for mono- and dimethylation at Lys 9 of histone H3 (H3K9me1 and H3K9me2) and forms predominantly the heteromeric complex as a G9a-GLP (G9a-like protein) that is a functional histone lysine methltransferase in vivo. Mounting evidence suggests that G9a catalyzes methylation of histone and nonhistone proteins, which plays a crucial role in diverse biological processes and human diseases. G9a have attracted great attention of scientists as an appealing antineoplastic target. Here, we review the current knowledge on biological functions of G9a, with particular emphasis on regulating gene expression and cell processes, and involvement in human diseases. We outline a perspective on various classes of G9a inhibitors to date from both articles and patents with an emphasis on their discovery, activity and the current research status. These hold future directions and opportunities for a rapid translation of G9a inhibitors into clinical practice for a number of aggressive cancers and other human diseases.

PMID: 27174055 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/1TcPIpd
via IFTTT

Synchronous giant hepatic adenoma in siblings-A case report and brief literature review

10.1080/15384047.2016.1177682<br/>Chengsheng Zhang

from Cancer via ola Kala on Inoreader http://ift.tt/1X9BWIP
via IFTTT

The Influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells

10.1080/15384047.2016.1177678<br/>Hongyao Zhang

from Cancer via ola Kala on Inoreader http://ift.tt/1ZQ2z4L
via IFTTT

Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells

10.1080/15384047.2015.1095399<br/>Yongqiang Chen

from Cancer via ola Kala on Inoreader http://ift.tt/1X9BREZ
via IFTTT

Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study

Hypothesis. Prior studies on patients with early B-cell lymphoid malignancies suggest that early intervention with curcumin may lead to delay in progressive disease and prolonged survival. These patients are characterized by increased susceptibility to infections. Rice bran arabinoxylan (Ribraxx) has been shown to have immunostimulatory, anti-inflammatory, and proapoptotic effects. We postulated that addition of Ribraxx to curcumin therapy may be of benefit. Study design. Monoclonal gammopathy of undetermined significance (MGUS)/smoldering multiple myeloma (SMM) or stage 0/1 chronic lymphocytic leukemia (CLL) patients who had been on oral curcumin therapy for a period of 6 months or more were administered both curcumin (as Curcuforte) and Ribraxx. Methods. Ten MGUS/SMM patients and 10 patients with stage 0/1 CLL were administered 6 g of curcumin and 2 g Ribraxx daily. Blood samples were collected at baseline and at 2-month intervals for a period of 6 months, and various markers were monitored. MGUS/SMM patients included full blood count (FBC); paraprotein; free light chains/ratio; C-reactive protein (CRP)and erythrocyte sedimentation rate (ESR); B2 microglobulin and immunological markers. Markers monitored for stage 0/1 CLL were FBC, CRP and ESR, and immunological markers. Results. Of 10 MGUS/SMM patients,5 (50%) were neutropenic at baseline, and the Curcuforte/Ribraxx combination therapy showed an increased neutrophil count, varying between 10% and 90% among 8 of the 10 (80%) MGUS/SMM patients. An additional benefit of the combination therapy was the potent effect in reducing the raised ESR in 4 (44%) of the MGUS/SMM patients. Conclusion. Addition of Ribraxx to curcumin therapy may be of benefit to patients with early-stage B-cell lymphoid malignancies.

from Cancer via ola Kala on Inoreader http://ift.tt/1OprBHh
via IFTTT

Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis: Regulation of p53 Signaling Pathway in HepG2 Cells In Vitro

Tetramethylpyrazine (TMP) was originally isolated from a traditional Chinese herbal medicine, Ligusticum chuanxiong. In the present study, TMP exhibits potent antitumor activities in vitro. However, the molecular mechanisms remain to be defined. Hence, this study aims to investigate the antiproliferative and apoptotic effects of TMP on HepG2 and elucidate the underlying mechanisms. Analyses using Cell Counting Kit-8 and real-time cell analyzer indicated that TMP significantly inhibited HepG2 cell proliferation. We also observed that TMP induced cell cycle arrest at the G0/G1 checkpoint and apoptosis, using flow cytometry and high-content screening. Furthermore, our results predicted that TMP could directly decrease mitochondrial membrane potential (m), increase the release of cytochrome c, and increase caspase activation, indicating that mitochondrial pathway apoptosis could be the mechanism for TMP within HepG2 cells. Moreover, TMP altered expression of p53 and the Bcl-2/Bax protein ratio, which revealed that TMP induced cell cycle arrest and caspase-dependent mitochondrial apoptosis in HepG2 cells in vitro. These studies provided mechanistic insights into the antitumor properties of TMP, which may be explored as a potential option for treatment of hepatocellular carcinoma.

from Cancer via ola Kala on Inoreader http://ift.tt/1Tc73P3
via IFTTT